Zhimin Hu, Yamei Han, Yuxiao Liu, Zehua Zhao, Fengguang Ma, Aoyuan Cui, Feifei Zhang, Zhengshuai Liu, Yaqian Xue, Jinyun Bai, Haifu Wu, Hua Bian, Y. Eugene Chin, Ying Yu, Zhuoxian Meng, Hua Wang, Yong Liu, Jiangao Fan, Xin Gao, Yan Chen, Yu Li – 30 August 2019
Csaba Matyas, Katalin Erdelyi, Eszter Trojnar, Suxian Zhao, Zoltan V. Varga, Janos Paloczi, Partha Mukhopadhyay, Balazs T. Nemeth, György Haskó, Resat Cinar, Robim M. Rodrigues, Yeni Ait Ahmed, Bin Gao, Pal Pacher – 30 August 2019
Zaid S. Ardalan, Sujievvan Chandran, Abhinav Vasudevan, Peter W. Angus, Andrew Grigg, Simon He, Graeme A. Macdonald, Simone I. Strasser, Courtney J. Tate, Glen A. Kennedy, Adam G. Testro, Paul J. Gow – 30 August 2019 – Erythropoietic protoporphyria (EPP) is an inherited metabolic disorder of heme synthesis resulting from overproduction of protoporphyrin IX (PPIX), which can lead to progressive liver disease characterized by recurrent EPP crises and end‐stage liver disease.
Jing Xiong, Tongyu Liu, Lin Mi, Henry Kuang, Xuelian Xiong, Zhimin Chen, Siming Li, Jiandie D. Lin – 30 August 2019
Tin‐Lok Wong, Kai‐Yu Ng, Kel Vin Tan, Lok‐Hei Chan, Lei Zhou, Noélia Che, Ruby L.C. Hoo, Terence K. Lee, Stéphane Richard, Chung‐Mau Lo, Kwan Man, Pek‐Lan Khong, Stephanie Ma – 30 August 2019
Joshua M. Adams, Kari A. Huppert, Eumenia C. Castro, Mario F. Lopez, Nima Niknejad, Sanjay Subramanian, Neda Zarrin‐Khameh, Milton J. Finegold, Stacey S. Huppert, Hamed Jafar‐Nejad – 30 August 2019
Jun Liu, Zhengsheng Wu, Dan Han, Chuansheng Wei, Yanyan Liang, Tongcui Jiang, Lu Chen, Manqi Sha, Yajie Cao, Fan Huang, Xiaoping Geng, Jishuang Yu, Yujun Shen, Hua Wang, Lijie Feng, Dong Wang, Shengyun Fang, Siying Wang, Yuxian Shen – 30 August 2019
Dennis D. Black, Cara Mack, Nanda Kerkar, Tamir Miloh, Shikha S. Sundaram, Ravinder Anand, Ashutosh Gupta, Estella Alonso, Ronen Arnon, Pinar Bulut, Saul Karpen, Chuan‐Hao Lin, Philip Rosenthal, Matthew Ryan, Robert H. Squires, Pamela Valentino, Sarah H. Elsea, Benjamin L. Shneider – 29 August 2019 – Ursodeoxycholic acid (UDCA) is commonly used to treat several liver disorders in adults and children, including primary sclerosing cholangitis (PSC) for which it is not U.S. Food and Drug Administration approved.
Yu Du, Gauri Khandekar, Jessica Llewellyn, William Polacheck, Christopher S. Chen, Rebecca G. Wells – 29 August 2019
Tangui Barré, Camelia Protopopescu, Firouzé Bani‐Sadr, Lionel Piroth, Teresa Rojas Rojas, Dominique Salmon‐Ceron, Linda Wittkop, Laure Esterle, Philippe Sogni, Karine Lacombe, Julie Chas, Olivia Zaegel, Marie‐Laure Chaix, Patrick Miailhes, Lawrence Serfaty, Fabienne Marcellin, Maria Patrizia Carrieri, ANRS CO13 HEPAVIH Study Group – 29 August 2019